Plunkett's Biotech & Genetics Industry Almanac 2018: Biotech, Pharmaceuticals, Drugs, Diagnostics & Genetics Industry Market Research, Statistics, Tre

ISBN-13: 9781628314502 / Angielski / Miękka / 2017 / 548 str.

Jack W. Plunkett

Opis

A complete reference guide to the business side of biotechnology, genetics, proteomics and related services. This new book contains complete profiles of the leading biotech companies; in-depth chapters on trends in genetics, technologies, statistics and finances; a handy glossary; and thorough indexes.

Spis treści

• Introduction 1
• How to Use This Book 3
• Chapter 1: Major Trends Affecting the Biotech & Genetics Industry 7
• 1) The State of the Biotechnology Industry Today 7
• 2) A Short History of Biotechnology 11
• 3) Ethanol Production Soared, But U.S. Federal Subsidy Expires 13
• 4) Cellulosic Ethanol Makes Slow Commercial Progress 14
• 5) Major Drug Companies Acquire or Partner With Smaller Biotech Firms 15
• 6) From Korea to India to Singapore to China, Nations Compete Fiercely in Biotech Development 15
• 7) Patients’ Genetic Profiles Plummet in Price as DNA Sequencing Technologies Advance 17
• 8) Gene Therapies Target Defective Genes/CRISPR Advances DNA Editing 19
• 9) Vaccines and Viruses in Drug Delivery 20
• 10) New Blockbuster Drugs Come to Market/ Drug Prices Soar 20
• 11) Generic Drugs Have Biggest Market Share by Unit Volume, but not by Total Revenues 22
• 12) Coupons and Other Marketing Schemes Obscure the Retail Prices of Drugs in the U.S., Which Are Vastly Higher than Prices Paid in Other Nations 22
• 13) Biotech and Orphan Drugs Create New Revenues for Drug Firms 24
• 14) Biosimilars (Generic Biotech Drugs) Receive FDA Guidelines for Accelerated Approval/Competition Will Be Fierce 24
• 15) Stem Cells—Multiple Sources Stem from New Technologies 26
• 16) Government Support for Stem Cell Research Evolves 26
• 17) Stem Cells—Therapeutic Cloning Techniques Advance 27
• 18) Stem Cells—A New Era of Tissue Replacement Takes Shape 28
• 19) Nanotechnology Converges with Biotech 29
• 20) Genetically Modified (GM) Seeds and Crops Planted in Dozens of Nations/Agribio R&D Investment Is High 30
• 21) Genetically Modified (GM) Foods Prompt Controversy, Labeling and Legislation 32
• 22) Cloning of Farm Animals/Meat and Cheese Substitutes Created in Laboratories/3-D Printed Food Appears 33
• 23) Selective Breeding, Zinc Fingers, Mutagenesis and Gene-Editing as Alternatives to GMOs 33
• 24) Immunotherapy Promises New Approach to Fighting Cancers 34
• 25) Technology Discussion—Genes and DNA 35
• 26) Technology Discussion—Proteins and Proteomics 36
• 27) Technology Discussion—DNA Chips 36
• 28) Technology Discussion—SNPs (“Snips”) 37
• 29) Technology Discussion—Synthetic Biology 37
• 30) Technology Discussion—Recombinant DNA 38
• 31) Technology Discussion—Polymerase Chain Reaction (PCR) 38
• Chapter 2: Biotech & Genetics Industry Statistics 39
• Biotech Industry Statistics and Market Size Overview 40
• The U.S. Drug Discovery & Approval Process 41
• U.S. FDA New Drug (NDA) and Biologic (BLA) Approvals, 2016 42
• U.S. Pharmaceutical R&D Spending Versus the Number of New Molecular Entity (NME) Approvals: 1993-2016 43
• Employment in Life & Physical Science Occupations by Business Type, U.S.: May 2016 44
• Federal R&D & R&D Plant Funding for General Science & Basic Research, U.S.: Fiscal Years 2015-2017 45
• U.S. Exports & Imports of Pharmaceutical Products: 2011-1st Quarter 2017 46
• U.S. Prescription Drug Expenditures, Aggregate & Per Capita Amounts, Percent Distribution: 2009-2025 47
• Prescription Drug Expenditures, U.S.: Selected Years, 1965-2025 49
• Total U.S. Biotechnology Patents Granted per Year by Patent Class: 1977-2015 50
• Research Funding for Biological Sciences, U.S. National Science Foundation: Fiscal Years 2016-2018 51
• Global Area of Biotech Crops by Country: 2016 52
• Domestic & Foreign Pharmaceutical Sales, PhRMA Member Companies: 1980-2015 53
• Sales By Geographic Area, PhRMA Member Companies: 2014 54
• Domestic U.S. Biopharmaceutical R&D & R&D Abroad, PhRMA Member Companies: 1980-2015 55
• Domestic U.S. Biopharmaceutical R&D & R&D Abroad Breakdown, PhRMA Member Companies: 2014 56
• Chapter 3: Important Biotech & Genetics Industry Contacts 57
• (Addresses, Phone Numbers and Internet Sites)
• Chapter 4: THE BIOTECH 400: Who They Are and How They Were Chosen 95
• Index of Companies Within Industry Groups 96
• Alphabetical Index 105
• Index of U.S. Headquarters Location by State 108
• Index of Non-U.S. Headquarters Location by Country 111
• Individual Profiles on Each of THE BIOTECH 400 115
• Additional Indexes
• Index of Hot Spots for Advancement for Women/Minorities 498
• Index by Subsidiaries, Brand Names and Selected Affiliations 500
• A Short Biotech & Genetics Industry Glossary 519